AnaptysBio (ANAB) Director John Schmid Receives Option Adjustments

What Happened

• Director John P. Schmid was subject to multiple derivative transactions on April 20, 2026 tied to a corporate separation. The filing shows matched dispositions to the issuer and corresponding grants/acquisitions (all at $0) that affected a total of 107,320 option shares (lots included: 15,000; 6,000; 6,000; 11,000; 11,000; 9,200; 10,600; 16,510; 16,510; 5,500). These were adjustments to option entitlements, not open-market buys or cash sales.

Key Details

• Transaction date: April 20, 2026; Form 4 filed April 22, 2026 (timely).
• Price: $0.00 for all listed derivative transactions (no cash changed hands).
• Total derivative shares affected: 107,320 (equal disposals to issuer and acquisitions).
• Shares owned after transaction: Not specified in the provided excerpt of the filing—check the full Form 4 for post-transaction holdings.
• Footnotes of note:
  • F1: Transactions are adjustments under the Separation and Distribution Agreement (Apr 20, 2026) that split existing options into separate options for First Tracks and AnaptysBio; Schmid acquired options to AnaptysBio shares per that agreement.
  • F2: Some option(s) are fully vested and exercisable.
  • F3: Some option(s) vest 1/12 monthly starting Feb 6, 2026, subject to continued service.
• Filing timeliness: No late filing indicator — appears timely.

Context

• These are derivative/option adjustments resulting from a corporate separation (spin-off), not exercises or cash sales. That means Schmid’s option entitlements were reallocated between the two companies; there was no immediate cash proceeds or market trade. Some of the adjusted options are already vested (or vest monthly), which affects when they could be exercised in the future.